Case report: Drug-induced vitiligo during treatment with BRAF/MEK inhibitors in a patient with metastatic conjunctival melanoma DOI
Seray Saray, Pelin Hızlı

Journal of Oncology Pharmacy Practice, Journal Year: 2023, Volume and Issue: unknown

Published: July 27, 2023

Autoimmune side effects can be detected during the use of BRAF/MEK inhibitor. Although its frequency, mechanism and importance are not known exactly, there cases reported in literature.We report a case drug-induced vitiligo patient with metastatic conjunctival malignant melanoma who was treated inhibition therapy.In case, controlled topical treatments. Follow-up process has been continuing no progression on month 12 current treatment.Although ICI-related autoimmune have described more frequently, may also occur secondary to BRAK/MEK inhibition. This points out that cutaneous toxicity is manageable delay treatment thanks collaboration dermatologists oncologists.

Language: Английский

Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics DOI
Sara Mahdiabadi, Sara Momtazmanesh, Amirali Karimi

et al.

Expert Review of Anticancer Therapy, Journal Year: 2023, Volume and Issue: 23(12), P. 1281 - 1293

Published: Nov. 1, 2023

Immune checkpoint inhibitors (ICIs) are one of the most promising approaches toward advanced melanoma. Here, we aimed to perform a meta-analysis randomized controlled trials (RCTs) evaluate efficacy all studied ICIs.

Language: Английский

Citations

6
Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies DOI
Riyad N. H. Seervai,

Avilasha Sinha,

Rajan P. Kulkarni

et al.

Clinical and Experimental Dermatology, Journal Year: 2022, Volume and Issue: 47(11), P. 1928 - 1942

Published: July 18, 2022

The discovery of immune checkpoint inhibition (ICI) sparked a revolution in the era targeted anticancer therapy. However, although monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 and programmed death-1 axes have improved survival patients with advanced cancers, these immunotherapies are associated wide spectrum dermatological immune-related adverse events (irAEs), ranging from mild to life-threatening. Several publications addressed clinical histopathological classification skin-directed irAEs, their impact on anti-tumour immunity survival, critical role supportive oncological dermatology management. In this paper, we review current understanding mechanistic drivers skin toxicities focus inflammatory, immunobullous melanocyte/pigment-related reactions. We detail specific immune-based mechanisms that may underlie different cutaneous also discuss potential as they relate extracutaneous irAEs lessons learned these, overlap techniques study differences vs. de novo reactions, how treatment AEs impacts cancer treatment, patient quality life overall survival. An basis will allow clinicians develop use blood-based biomarkers could help ultimately predict onset and/or severity implement rational mechanistic-based strategies while potentially avoiding reducing effect ICIs.

Language: Английский

Citations

9
Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study DOI Open Access

Nicola Hermann,

Lara Valeska Maul,

Milad Ameri

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(19), P. 4576 - 4576

Published: Sept. 21, 2022

Vitiligo-like depigmentation (VLD) is an immune-related adverse event (irAE) of checkpoint-inhibitor (CPI) treatment, which has previously been associated with a favourable outcome. The aim this study was to explore clinical, biological and prognostic features melanoma patients VLD under CPI-treatment whether they exhibit characteristic immune response profile in peripheral blood. Melanoma developing CPI were included prospective observational single-center cohort study. We collected analysed clinical parameters, photographs serum from 28 patients. They received pembrolizumab (36%), nivolumab (11%), ipilimumab/nivolumab (32%) or trial medications (21%). performed high-throughput proteomics assay (Olink), we identified distinct proteomic signature comparison non-VLD Our assessments revealed that lesions had predominantly symmetrical distribution pattern, mostly smaller “freckle-like” macules preferential UV-exposed areas. Patients previous targeted therapy showed significantly longer time lapse between initiation onset compared non-pre-treated (12.5 vs. 6.25 months). Therapy responders exhibited when non-responders such as upregulation EDAR downregulation LAG3. ITGA11 elevated the VLD-group non-VLD-CPI-treated findings demonstrate on level, characterized by CPI-treated without responsiveness reflected profile. pathomechanisms underlying these how could relate antitumoral remain be elucidated.

Language: Английский

Citations

9
Cutaneous Events Associated with Immunotherapy of Melanoma: A Review DOI Open Access
Lorenza Burzi, Aurora Alessandrini, Pietro Quaglino

et al.

Journal of Clinical Medicine, Journal Year: 2021, Volume and Issue: 10(14), P. 3047 - 3047

Published: July 8, 2021

Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review principal pigmentation changes induced by immune check-point inhibitors: appearance of vitiligo, Sutton phenomenon, melanosis hair nail toxicities.

Language: Английский

Citations

11
Differences in the immune microenvironment between improved and non-improved cases of vitiligo after halo nevus excision DOI

Shinji Kano,

Motoki Nakamura,

Yuka Nojiri

et al.

Journal of Dermatological Science, Journal Year: 2023, Volume and Issue: 109(3), P. 136 - 142

Published: March 1, 2023

Language: Английский

Citations

4
Chemical profiling and enzyme inhibitory properties of essential oil isolated from Artemisia judaica grown in Egypt: GC-MS analysis and in-Vitro studies DOI
Heba A. S. El‐Nashar, Omayma A. Eldahshan,

Nilofar Nilofar

et al.

Natural Product Research, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 5

Published: July 17, 2024

L. is a desert aromatic herb with characteristic fragrance and taste belonging to the family Asteraceae. This study aimed evaluate chemical composition of essential oil isolated from

Language: Английский

Citations

1
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response DOI
Elena Carmona‐Rocha, Ivana Sullivan, Oriol Yélamos

et al.

Melanoma Research, Journal Year: 2023, Volume and Issue: 33(6), P. 553 - 555

Published: Oct. 25, 2023

aDermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma Barcelona bInstitut d'Investigació Biomèdica Pau (IIB SANT PAU) cOncoloy Barcelona, Spain Received 27 January 2023 Accepted 26 July 2023. Correspondence to Elena Carmona-Rocha, Dermatology Mas Casanovas 90, 08041 Spain, Tel: +34 935537007; fax: 935537008; e-mail: [email protected]

Language: Английский

Citations

2
A20 deficiency in myeloid cells deteriorates the onset of vitiligo in mice DOI Open Access
He Li,

Congpin Wang,

Xiaoqing Li

et al.

Dermatologic Therapy, Journal Year: 2021, Volume and Issue: 34(3)

Published: March 2, 2021

Melanocyte-specific CD8+T cells enrichment correlates with the severity of vitiligo, and role A20 derived from myeloid in pathogenic T is unknown. Premelanosome (PMEL)-specific transgenic were adoptive transferred into Krt14-Kitl* mice to construct vitiligo model, which was further mated A20MKO IKK2fl/fl mice. Bone marrow stimulated 30% L929 cell-conditioned medium, Fc-human tumor necrosis factor, lipopolysaccharides induce bone marrow-derived macrophages (BMDMs). The relative expression CCL2, CCL5, IL12A detected real-time PCR, nuclear factor kappa B (NFκB) related molecules Western blots. Fluorescence-activated cell sorting (FACS) utilized assay percent innate adaptive immune spleen marrow, CD45+T skin. Down-regulated skin biopsies patients. deficiency did not affect development cells, macrophages, neutrophils. negatively regulated induction proinflammatory chemokines (CCL2, IL12A) NFκB-related molecule BMDMs, could be blocked by NFκB knockout. It revealed that onset diminished CD45+ enrichment, also reversed deteriorate mice, can considered as a treatment target.

Language: Английский

Citations

5
Transcriptome Analysis Reveals the Molecular Immunological Characteristics of Lesions in Patients with Halo Nevi When Compared to Stable Vitiligo, Normal Nevocytic Nevi and Cutaneous Melanoma DOI Creative Commons
Chun Pan,

Jingzhe Shang,

Haiqin Jiang

et al.

Journal of Inflammation Research, Journal Year: 2021, Volume and Issue: Volume 14, P. 4111 - 4124

Published: Aug. 1, 2021

Given their similar appearance and histology, halo nevi (HN) were considered as a type of vitiligo. However, whether HN have stronger immune response than stable vitiligo (VL) remains unclear. In addition, the molecular alterations in compared with normal nevocytic (NN) primary cutaneous melanoma (MM) must be determined. This study aimed to systematically characterize immunological features HN.Skin samples from patients HN, VL, NN, MM obtained informed consent. Each four groups underwent transcriptome sequencing data analysis for pairwise comparison. Quantitative real-time PCR (RT-qPCR) was conducted confirm transcriptional expression some differentially expressed genes (DEGs) that closely related immunity.A total 441 1507 DEGs found HN/NN HN/MM groups, respectively. Compared those lesions contained 162 up-regulated 12 down-regulated DEGs. Bioinformatics showed substantially enriched response, deficiency, rejection; biological stimulation (virus, bacteria); proliferation activation cells. Immune cell composition also confirmed high levels multiple immunocytes HN.The mechanisms VL similar, but activity VL. Innate adaptive immunity involved pathogenesis progression

Language: Английский

Citations

4
Vitíligo facial como fenómeno paraneoplásico de un melanoma rectal metastásico DOI

Alejandra Fajardo Peña,

Lorena Contreras Becerra,

Sandra Isabel Chinchilla Olaya

et al.

Piel, Journal Year: 2024, Volume and Issue: 39(10), P. 651 - 653

Published: July 22, 2024

Citations

0